Datopotamab Deruxtecan for Advanced or Metastatic HR+/HER2− and Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
J. Clin. Oncol 2024 Apr 23;[EPub Ahead of Print], A Bardia, IE Krop, T Kogawa, D Juric, AW Tolcher, EP Hamilton, T Mukohara, A Lisberg, T Shimizu, AI Spira, J Tsurutani, S Damodaran, KP Papadopoulos, J Greenberg, F Kobayashi, H Zebger-Gong, R Wong, Y Kawasaki, T Nakamura, F Meric-BernstamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.